Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PBYI
Previous Symbol
CUSIPN/A
Phone424-248-6500
Debt
Debt-to-Equity Ratio2.64
Current Ratio3.01
Quick Ratio2.96
Price-To-Earnings
Trailing P/E Ratio-2.88
Forward P/E Ratio-7.08
P/E GrowthN/A
Sales & Book Value
Annual Sales$26.20 million
Price / Sales32.86
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.42 per share
Price / Book15.90
Profitability
EPS (Most Recent Fiscal Year)($7.85)
Net Income$-291,950,000.00
Net Margins-73.45%
Return on Equity-301.41%
Return on Assets-74.05%
Miscellaneous
Employees318
Outstanding Shares38,130,000
Market Cap$920.96 million
OptionableOptionable
Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions
What is Puma Biotechnology's stock symbol?
Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."
How were Puma Biotechnology's earnings last quarter?
Puma Biotechnology Inc (NASDAQ:PBYI) posted its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.97) by $0.60. The biopharmaceutical company earned $62.60 million during the quarter, compared to analysts' expectations of $57.94 million. Puma Biotechnology had a negative return on equity of 301.41% and a negative net margin of 73.45%. The business's quarterly revenue was up 926.2% on a year-over-year basis. During the same quarter last year, the firm earned ($1.36) EPS. View Puma Biotechnology's Earnings History.
When is Puma Biotechnology's next earnings date?
What price target have analysts set for PBYI?
11 brokerages have issued twelve-month price targets for Puma Biotechnology's stock. Their forecasts range from $23.00 to $151.00. On average, they expect Puma Biotechnology's share price to reach $68.30 in the next year. This suggests a possible upside of 202.5% from the stock's current price. View Analyst Price Targets for Puma Biotechnology.
What is the consensus analysts' recommendation for Puma Biotechnology?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 3 sell ratings, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Puma Biotechnology.
What are Wall Street analysts saying about Puma Biotechnology stock?
Here are some recent quotes from research analysts about Puma Biotechnology stock:
- 1. According to Zacks Investment Research, "Puma Biotech incurred narrower-than-expected loss in Q3. Its only marketed drug, Nerlynx, approved for early stage HER2-positive breast cancer, have improved sales steadily since launch in July 2017. The drug was also approved in the EU during September, which can generate additional sales in the future quarters. However, sale of the drug in the third quarter of 2018 fell below expectations due to higher patient discontinuation. Meanwhile, several additional studies on Nerlynx targeting different types of breast cancer patient populations and in earlier-line settings are currently underway. The drug’s label expansion will allow it to treat and access an expanded patient population. Shares have underperformed the industry so far this year. Due to the lack of a strong pipeline, the company is totally dependent on Nerlynx for growth. Hence, any kind of regulatory setback for Nerlynx could affect the company’s growth prospects." (11/14/2018)
- 2. Cantor Fitzgerald analysts commented, ": We are lowering our 12-month price target to $50 from $75, but are maintaining our Overweight rating on shares of PBYI. Puma reported Nerlynx sales of $53M, which was under FactSet consensus of $58M. We are not necessarily lowering the price target due to the miss, but rather the explanations behind what are driving Nerlynx trends. We have slowed the ramp, increased discontinuations, and our 2025 Nerlynx revenues are $760M vs. $1.02B. We find the communication patterns related to the Nerlynx launch as highly challenging and tough to interpret. We increased the discount rate from 10% to 11% to proxy our view that we have lower visibility into these launch trends." (11/2/2018)
Has Puma Biotechnology been receiving favorable news coverage?
Media coverage about PBYI stock has trended somewhat positive recently, InfoTrie reports. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Puma Biotechnology earned a news impact score of 1.2 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days.
Who are some of Puma Biotechnology's key competitors?
Some companies that are related to Puma Biotechnology include Taro Pharmaceutical Industries (TARO), FibroGen (FGEN), Array Biopharma (ARRY), Horizon Pharma (HZNP), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT), Agios Pharmaceuticals (AGIO), Ligand Pharmaceuticals (LGND), Evotec (EVTCY), Akcea Therapeutics (AKCA), Ascendis Pharma A/S (ASND), Allakos (ALLK), Blueprint Medicines (BPMC), Endo International (ENDP) and Ultragenyx Pharmaceutical (RARE).
Who are Puma Biotechnology's key executives?
Puma Biotechnology's management team includes the folowing people:
- Mr. Alan H. Auerbach, Founder, Chairman, Pres, CEO & Sec. (Age 48)
- Dr. Richard P. Bryce, Chief Medical & Scientific Officer (Age 61)
- Mr. Charles R. Eyler, Sr. VP of Fin. & Admin. and Treasurer (Age 70)
- Mr. Steven Lo, Chief Commercial Officer (Age 51)
- Mr. Maximo F. Nougues, CFO & Principal Accounting Officer (Age 49)
Who are Puma Biotechnology's major shareholders?
Puma Biotechnology's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.39%), Vanguard Group Inc (7.39%), BlackRock Inc. (6.88%), Janus Henderson Group PLC (5.63%), Partner Fund Management L.P. (4.86%) and FMR LLC (3.62%). Company insiders that own Puma Biotechnology stock include Adage Capital Partners Gp, LL, Alan H Auerbach, Charles R Eyler, Richard Paul Bryce and Robert Charnas. View Institutional Ownership Trends for Puma Biotechnology.
Which institutional investors are selling Puma Biotechnology stock?
PBYI stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Jennison Associates LLC, FMR LLC, Point72 Asset Management L.P., Emerald Advisers Inc. PA, Franklin Resources Inc., Emerald Mutual Fund Advisers Trust and Marshall Wace North America L.P.. Company insiders that have sold Puma Biotechnology company stock in the last year include Alan H Auerbach, Charles R Eyler and Richard Paul Bryce. View Insider Buying and Selling for Puma Biotechnology.
Which institutional investors are buying Puma Biotechnology stock?
PBYI stock was acquired by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, Partner Fund Management L.P., Candriam Luxembourg S.C.A., Macquarie Group Ltd., Alliancebernstein L.P., BlackRock Inc., TIAA CREF Investment Management LLC and Pictet Asset Management Ltd.. View Insider Buying and Selling for Puma Biotechnology.
How do I buy shares of Puma Biotechnology?
Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Puma Biotechnology's stock price today?
One share of PBYI stock can currently be purchased for approximately $22.58.
How big of a company is Puma Biotechnology?
Puma Biotechnology has a market capitalization of $920.96 million and generates $26.20 million in revenue each year. The biopharmaceutical company earns $-291,950,000.00 in net income (profit) each year or ($7.85) on an earnings per share basis. Puma Biotechnology employs 318 workers across the globe.
What is Puma Biotechnology's official website?
How can I contact Puma Biotechnology?
Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]
MarketBeat Community Rating for Puma Biotechnology (NASDAQ PBYI)
MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote "Outperform" if you believe PBYI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PBYI will underperform the S&P 500 over the long term. You may vote once every thirty days.
